2025-06-13-花旗集团-卡地纳健康（CAH）_卡地纳健康（CAH.N）_卡地纳健康投资者日回顾_言出必行_23页_833kb

Cardinal Health Investor Day Summary

Core Content and Key Highlights

Cardinal Health (CAH.N) held an Investor Day on June 12, 2025, showcasing significant progress in its specialty solutions and non-pharma growth areas. The company's strategy focuses on strengthening its position in the pharmaceutical and specialty markets while addressing the ongoing challenges in the Global Medical Products and Distribution (GMPD) segment, primarily due to tariffs. Despite these challenges, CAH has demonstrated its ability to grow branded products above market rates and has implemented cost-simplification measures. The company also introduced FY26 guidance ahead of expectations, emphasizing the strength of its Pharma and Other segments.

Main Points and Strategic Focus

Specialty Solutions and MSO Growth

• Specialty Business Growth: CAH's specialty business is expected to generate $40B in revenue by FY28, with a 14% 3-year CAGR.
• MSO Strategy: CAH has expanded its MSO presence, now managing ~2,200 providers and generating ~$3B in revenue, primarily through the GIA acquisition platform.
• Specialty Network: Introduced "The Specialty Network," a multi-specialty MSO platform for Autoimmune, Urology, and Oncology, which complements its existing oncology-focused MSO (Navista + ION).
• Revenue Diversity: Autoimmune and Urology provide more revenue diversity compared to Oncology, with ~40% of practice revenue from infusion and ancillary services versus 94% for medical oncology.
• Growth Potential: CAH expects Autoimmune and Urology to grow at 8% and 7% respectively from 2024 to 2029.

BioPharma Solutions

• Growth Targets: CAH aims for its biopharma solutions to generate ~$1B in revenue by FY28, up from ~$550M in FY25.
• 3PL and Sonexus: CAH's 3PL business services 63% of new drug launches, and Sonexus is expected to grow the number of supported therapies by >125% by FY28.
• Advanced Therapy Solutions: Expected to benefit from the increasing number of cell and gene therapy launches, with Evaluate Pharma predicting 183 approved therapies by 2030.

At-Home Solutions

• Market Expansion: CAH's at-Home business is projected to grow to $3.5B in FY25 and serve ~10M patients within five years.
• Complementary Businesses: The acquisition of ADSG has enhanced CAH's Home Health segment, combining B2B and DTC distribution.
• Diabetes Opportunity: CAH estimates a $17B TAM for CGMs, with 65% of qualifying diabetics not yet using them, expecting a 10% CAGR.
• HME Market: The HME market is valued at $45B and is expected to grow at 8% CAGR.

GMPD Segment

• Tariff Impact: GMPD faces challenges mainly due to tariffs, with a gross impact of $150-$200M in FY26 (down from $200-$300M previously).
• Mitigation Efforts: CAH expects to offset ~$100-$125M of the tariff impact through U.S. capacity expansion, supplier diversification, and price increases.
• Net Impact: The net impact of tariffs is expected to be $50-$75M in FY26.
• Footprint: ~35% of CAH Brand COGS are in the U.S., with ~20% in Mexico/Canada, ~10% in China, and the rest across other regions.
• GMPD Revenue and EBIT: Expected to grow at 3-5% YoY, with EBIT at $140M (1.1% margin), beating prior estimates.

Financial Highlights

Earnings and Revenue Projections

Segment Guidance

Profit Mix Shift

• Pharma and Specialty: Expected to drive 60% of operating profit.
• Other: Expected to contribute 29%.
• GMPD: Expected to contribute 11%.

Capital Deployment and Leverage

• Capital to Deploy (FY26-FY28): $11B, including $10B from FCF and $1B in excess cash.
• Capital Priorities:
  • ~$3.7B for return of capital (~$1.5B in dividends, ~$2.2B in repurchases)
  • ~$1B in opioid litigation payments
  • ~$1B in debt repayments
  • ~$1B in tuck-in M&A
  • $5B in opportunistic strategic M&A or share repurchases
• Leverage Ratios: Debt/LTM EBITDA is expected to rise to 3.5x by the end of 4Q25, with a target to return to 2.75-3.25x within 12-18 months.

Valuation and Financial Ratios

Outlook and Policy Considerations

• MFN Policy Impact: CAH believes they can navigate potential changes to WAC through fair compensation with manufacturing partners. They also anticipate a mechanism to support providers.
• Tariff Strategy: CAH expects to mitigate the impact of tariffs through U.S. capacity expansion and supplier diversification, while also managing price increases.
• Long-Term Growth: CAH expects Pharma revenue to grow at 8-10% CAGR and EBIT at 7-9% CAGR, with a normalized growth of 5-7%.
• Other Segment Growth: Expected to grow at 26-28% CAGR (10-12% normalized) and EBIT at 25-27% CAGR.

Conclusion

Cardinal Health has made significant strides in strengthening its specialty and non-pharma segments, while also addressing challenges in GMPD. The company has raised guidance for FY25 and introduced FY26 guidance ahead of expectations, driven by strong performance in Pharma and Other segments. CAH remains committed to its long-term growth strategy, with a focus on increasing profitability and maintaining a competitive edge in the evolving healthcare landscape.